Search - tctmd.com

Displaying 1 - 20 of 43

Sort: Relevancy | Date

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

News Daily News

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

Michael O'Riordan

July 29, 2024

News Daily News

Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies

Michael O'Riordan

December 19, 2023

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

News Conference News AHA 2023

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

Caitlin E. Cox

November 12, 2023

News Daily News

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

Michael O'Riordan

September 14, 2023

News Conference News EAS 2023

With New LDL Goalposts in FH, Combo Therapy Must Start Early

Michael O'Riordan

May 29, 2023

News Conference News EAS 2023

Multipronged Outreach to Families Can Boost FH Cascade Screening: IMPACT-FH

Michael O'Riordan

May 26, 2023

News Daily News

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

Michael O'Riordan

November 17, 2022

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Conference News EAS 2022

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

Michael O'Riordan

May 26, 2022

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

News Daily News

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

Michael O'Riordan

December 22, 2021

News Daily News

Heterozygous FH Diagnosed Late, Remains Undertreated

Michael O'Riordan

September 13, 2021

News Conference News EAS 2021

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

Michael O'Riordan

June 03, 2021

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

News Daily News

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Caitlin E. Cox

March 24, 2020

Advertisement

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

With New LDL Goalposts in FH, Combo Therapy Must Start Early

Multipronged Outreach to Families Can Boost FH Cascade Screening: IMPACT-FH

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

Heterozygous FH Diagnosed Late, Remains Undertreated

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content